PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
Raúl Rincón(Universidad Autónoma de Madrid), Federico Rojo(Hospital Universitario Fundación Jiménez Díaz)
Cited by 100
Related Papers
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
|Journal of Clinical Oncology|2005|409
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
|Cancers|2020|37
CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
|Journal of Clinical Medicine|2022|7